Home › Compare › SICRF vs ABBV
SICRF yields 1.06% · ABBV yields 3.12%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, SICRF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of SICRF + ABBV for your $10,000?
SimCorp A/S, together with its subsidiaries, provides investment management solutions for asset management, fund management, insurance, life/pension, central banks, asset servicing, treasury, sovereign wealth, and wealth management companies. It provides SimCorp Dimension, an integrated front-to-back investment management solution; SimCorp Sofia, a front-to-back investment management solution for the Italian insurance market; SimCorp Gain, an enterprise data management solution for reference and market data management; and SimCorp Coric, a solution for client communications and reporting automation. The company also offers front office solutions, including asset, alternative investment, order, and compliance manager; and back office solutions comprising settlement, corporate actions, cash and securities, investment accounting, collateral, general ledger, and fund administration manager. In addition, it provides middle office solutions consisting of strategy, risk analysis, and performance manager; and data and reporting solutions, which include client communications, data warehouse manager, reconciliation, and enterprise data manager. The company has operations in North America, Europe, the Middle East, Africa, and the Asia Pacific. SimCorp A/S was founded in 1971 and is headquartered in Copenhagen, Denmark.
Full SICRF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.